This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kumar, P. Articles by DiPaola, R. S. Search for Related Content PubMed PubMed Citation Articles by Kumar, P. Articles by DiPaola, R. S. Social Bookmarking                            What's this?

Phase I Trial of Weekly Docetaxel With Concurrent Three-Dimensional Conformal Radiation Therapy in the Treatment of Unfavorable Localized Adenocarcinoma of the Prostate

From the Department of Radiation Oncology, University of Southern California Keck School of Medicine, Los Angeles, CA; Divisions of Medical Oncology and Urology and Departments of Surgery and Medicine, Cancer Institute of New Jersey, Robert Wood Johnson Medical School, University of Medicine & Dentistry of New Jersey, New Brunswick, NJ.

Address reprint requests to Parvesh Kumar, MD, Department of Radiation Oncology, University of Southern California Keck School of Medicine, 1441 Eastlake Ave, NOR G356, Los Angeles, CA 90033-0804; e-mail: parveshk{at}usc.edu

PURPOSE: A phase I trial was conducted to determine the maximally tolerated dose (MTD) of concurrent weekly docetaxel and three-dimensional conformal radiation therapy (3-D CRT) in unfavorable localized adenocarcinoma of the prostate.

PATIENTS AND METHODS: Patients with unfavorable localized adenocarcinoma of the prostate underwent daily 3-D CRT to a total dose of 70.2 Gy at 1.8 Gy/fraction and concurrent docetaxel given once a week for 8 to 9 weeks. The initial weekly docetaxel dose level was 5 mg/m² and the docetaxel doses were escalated as follows: 8, 12, 16, 20, and 25 mg/m².

RESULTS: Between January 2000 and August 2002, 22 men completed the chemoradiation therapy protocol. The dose-limiting toxicity was grade 3 diarrhea, which occurred in the first two patients treated at the 25 mg/m² docetaxel dose level. The MTD of weekly docetaxel was determined to be 20 mg/m². The overall incidence of grade 2 diarrhea and grade 2 dysuria was 36% and 23%, respectively. Seven (32%) and 15 (68%) patients did not experience any diarrhea or dysuria, respectively. No neutropenia or thrombocytopenia was observed. One patient required intermittent urinary catherization 10 months postcompletion of therapy, which resolved without any surgical intervention. Seventeen patients remain in prostate-specific antigen remission. At a median follow-up interval of 8 months (range, 2 to 27 months), all patients are alive.

CONCLUSION: Concurrent weekly docetaxel in conjunction with 3-D CRT is well tolerated with acceptable toxicity. The MTD of weekly docetaxel was determined to be 20 mg/m² with concurrent 3-D CRT.

Supported partially by a grant from Aventis Pharmaceuticals.

Authors' disclosures of potential conflicts of interest are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				N. J. Sanfilippo, S. S. Taneja, A. Chachoua, H. Lepor, and S. C. Formenti Phase I/II Study of Biweekly Paclitaxel and Radiation in Androgen-Ablated Locally Advanced Prostate Cancer J. Clin. Oncol., June 20, 2008; 26(18): 2973 - 2978. [Abstract] [Full Text] [PDF]

				M. A. Carducci What Is More Exciting? The Activity of Docetaxel in Early Prostate Cancer or the Successful Collaboration Between Urologists and Medical Oncologists to Complete a Study in Early Prostate Cancer? J. Clin. Oncol., May 20, 2005; 23(15): 3304 - 3307. [Full Text] [PDF]